Institute of Biopharmaceutical Science, School of Pharmaceutical Science, National Yang-Ming University, Taipei City 112, Taiwan, Republic of China.
Metabolism. 2011 Jun;60(6):888-92. doi: 10.1016/j.metabol.2010.08.009. Epub 2010 Oct 30.
The aim of this study was to evaluate the effect and elucidate the potential mechanism of the extract of rhizomes from Dioscorea alata L. cv. Phyto, Dispo85E, on accelerating the elimination of advanced glycation end products (AGEs) in vitro and in vivo. Primary mouse nonparenchymal cells (NPCs) were used to evaluate the drug effect on AGEs clearance and autophagic-lysosomal activity. In an animal study, we used AGEs-induced diabetic mice to evaluate the drug effect on AGEs-induced vascular complications. Our results indicated that Dispo85E enhanced the endocytosis and degradation activity of AGEs in hepatic NPCs. Furthermore, the hepatocyte growth factor (HGF) expression level was positively correlated with the clearance capacity of the AGEs in NPCs after Dispo85E treatment. In addition, the effects of Dispo85E on the degradation and uptake capability of (14)C-AGEs were abolished in the presence of an anti-HGF neutralizing antibody. We further demonstrated that recombinant mouse HGF could enhance the endocytosis and autophagic clearance of AGEs in NPCs. The in vivo data indicated that Dispo85E increased hepatic HGF messenger RNA expression levels and decreased serum AGEs level in diabetic mice. Moreover, the function of retina and kidneys was improved by Dispo85E treatment in AGEs-induced diabetic mice. These results suggest that HGF may have an important role in the elimination of AGEs. This study suggests that Dispo85E is a botanical drug with a novel mechanism that enhances the clearance of AGEs through HGF-induced autophagic-lysosomal pathway and is a candidate drug for the treatment of diabetic vascular complications.
本研究旨在评估薯蓣属植物根茎提取物 Dispo85E 加速体外和体内晚期糖基化终产物 (AGEs) 清除的作用及其潜在机制。原代小鼠非实质细胞 (NPC) 用于评估药物对 AGEs 清除和自噬溶酶体活性的影响。在动物研究中,我们使用 AGEs 诱导的糖尿病小鼠评估药物对 AGEs 诱导的血管并发症的影响。我们的结果表明,Dispo85E 增强了 NPC 中 AGEs 的内吞和降解活性。此外,在 Dispo85E 处理后,HGF 表达水平与 NPC 中 AGEs 的清除能力呈正相关。此外,当存在抗 HGF 中和抗体时,Dispo85E 对 (14)C-AGEs 的降解和摄取能力的影响被消除。我们进一步证明,重组小鼠 HGF 可以增强 NPC 中 AGEs 的内吞和自噬清除。体内数据表明,Dispo85E 增加了糖尿病小鼠肝脏 HGF 信使 RNA 表达水平并降低了血清 AGEs 水平。此外,Dispo85E 治疗可改善 AGEs 诱导的糖尿病小鼠的视网膜和肾脏功能。这些结果表明 HGF 可能在 AGEs 的清除中起重要作用。本研究表明,Dispo85E 是一种具有增强 HGF 诱导的自噬溶酶体途径清除 AGEs 作用的新型机制的植物药,是治疗糖尿病血管并发症的候选药物。